Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for this news story on new funding for CVM. Very good to see that they have raised another million dollars to push their phase 3 clinical trials forward. This company can be a big success when Multikine is approved. I am optimistic.
Great to see DDCC has been moving up with large buying last week and this week. The Translock is ready this year to go into service in many different industries and investors are buying in anticipation of the first contracts. I think we will see a lot more as this year plays out. So much potential in this little company and its technology.
Thanks. That's the news I was remembering about seven patents for Double Crown's Translock. It looks like the company is getting ready for a big marketing year. Also, I see the trading volume and bidding on the stock is starting to pick up lately. I see over 1.5 million were bought today and the bid price keeps inching higher. Looking good as this year starts out.
I remember from one of the recent DDCC announcements that there are now seven separate patents filed on the Translock. This shows the company is very serious about holding its exclusive control over this technology which will be so valuable to the world shipping markets. I am also looking forward to more news from Double Crown and expect we will be seeing it soon.
ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the submission of a Marketing Authorization Application (MAA) for its investigational oral anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the European Medicines Agency (EMA). ARIAD is seeking marketing approval in the European Union of brigatinib in adult patients with anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) who have been previously treated with crizotinib. The U.S. Food and Drug Administration (FDA) is currently reviewing a New Drug Application for brigatinib filed by ARIAD and has set an action date of April 29, 2017 under the Prescription Drug User Fee Act (PDUFA).
“ARIAD's submission of the brigatinib MAA to the EMA is one of many recent milestones highlighting our strong investment in internally discovered rare cancer therapies,” said Paris Panayiotopoulos, president and chief executive officer of ARIAD. “Since announcing our definitive agreement to combine with Takeda, we remain focused on our accountability to our patients by propelling brigatinib forward and by preparing for its anticipated U.S. launch.”
“The brigatinib clinical trials have provided patients with refractory ALK+ NSCLC, including those patients who have metastatic brain lesions, with a potential important treatment option,” said Maurice Perol, MD, Léon Bérard Cancer Center, Lyon, France. “Based on the clinical data we’ve seen to date, we are really excited by the prospect that appropriate patients in the EU may have access to brigatinib as a new targeted treatment.”
ARIAD’s MAA submission includes clinical data from its Phase 1/2 and pivotal Phase 2 ALTA trials of brigatinib. Results from the ALTA trial and central nervous system (CNS) activity in the ALTA and Phase 1/2 trials were reported at the International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer (WCLC) in December 2016. In the ALTA trial, 222 patients received either 90 mg of brigatinib once per day (QD) continuously or 180 mg QD, preceded by a lead-in dose of 90 mg QD for seven days. Data from the ALTA trial demonstrated that of 110 patients on the 180-mg regimen QD with a seven-day lead-in at 90 mg QD with a median follow-up of 11.0 months, 55 percent achieved confirmed objective response as assessed by the investigator. In this arm, the median progression-free survival (PFS) was 15.6 months in this post-crizotinib setting, by both investigator and independent review committee (IRC) assessment. Additionally, in this arm, 67 percent (12/18) of patients with measurable brain metastases achieved a confirmed intracranial objective response. The most common treatment-emergent adverse events (TEAEs; ≥ 25% of all patients in this arm, regardless of relationship to treatment), were nausea (43%), fatigue (40%), diarrhea (39%), cough (36%), increased blood creatine phosphokinase (CPK) (33%), headache (30%), rash (28%), and vomiting (26%). The most common serious adverse reactions other than neoplasm progression reported in 2% or more of patients included pneumonia (5.0%), pneumonitis (5.0%) and epilepsy (2.3%). A subset of pulmonary adverse events (AEs) with early onset (median: Day 2; range: Day 1-9) occurred in 6.4 percent of all patients (grade ≥3 in 3% of patients); no such events with early onset occurred after dose escalation to 180 mg QD following the lead-in dose of 90 mg for seven days.
About Brigatinib
Brigatinib is an investigational, targeted cancer medicine discovered internally at ARIAD. It is in development for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). The global Phase 2 ALTA trial, in patients with locally advanced or metastatic ALK+ NSCLC who were previously treated with crizotinib, is the primary basis for brigatinib’s initial regulatory review. ARIAD has also initiated the Phase 3 ALTA 1L trial to assess the efficacy and safety of brigatinib in comparison to crizotinib in patients with locally advanced or metastatic ALK+ NSCLC who have not received prior treatment with an ALK inhibitor. More information on brigatinib clinical trials can be found here.
Brigatinib received Breakthrough Therapy designation from the FDA for the treatment of patients with ALK+ NSCLC whose tumors are resistant to crizotinib, and was granted Orphan Drug designation by the FDA for the treatment of ALK+, ROS1+ and EGFR+ NSCLC.
About ALK+ NSCLC
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 80 to 85 percent of the estimated 222,500 new cases of lung cancer diagnosed each year in the United States, according to the American Cancer Society. Anaplastic lymphoma kinase (ALK) was first identified as a chromosomal rearrangement in anaplastic large-cell lymphoma (ALCL). Genetic studies indicate that chromosomal rearrangements in ALK are key drivers in a subset of NSCLC patients as well. Approximately five percent of patients with NSCLC have a rearrangement in the ALK gene, according to the American Cancer Society.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. On January 9, 2017, it was announced that ARIAD has entered into a definitive agreement to be acquired by Takeda. The transaction is expected to close by the end of February 2017, subject to customary closing conditions. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
Forward-Looking Statements
This press release contains forward-looking statements. Any statements contained herein which do not describe historical facts, including, but not limited to, statements regarding regulatory filings for brigatinib and the therapeutic potential of brigatinib, the anticipated timing for approval of brigatinib in the United States, the announced merger between ARIAD and Takeda, ARIAD’s continued efforts to develop brigatinib, ARIAD’s plans for the potential U.S. launch of brigatinib, and the potential of brigatinib as a new treatment option, are forward-looking statements which are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, among others: risks related to the satisfaction of the conditions to closing the Takeda acquisition (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including uncertainties as to how many of ARIAD’s stockholders will tender their shares in the tender offer and the possibility that the acquisition does not close; early-stage clinical data may not be replicated in later-stage clinical studies; the costs associated with our research, development, manufacturing and other activities; the adequacy of our capital resources and the availability of additional funding; our ongoing and additional clinical trials of brigatinib may not be successful or initiated, enrolled or conducted in a timely manner; our ability to meet anticipated regulatory filing and approval dates for brigatinib; regulatory developments and safety issues, including difficulties or delays in obtaining regulatory and pricing and reimbursement approvals for brigatinib; competitive risks; manufacturing issues; the uncertainties inherent in research and development, including the ability to sustain and increase the rate of growth in revenues for ARIAD’s products despite increasing competitive, reimbursement and economic challenges; whether and when any drug applications may be filed in any jurisdictions for any indications or any additional indications for ARIAD’s products or for ARIAD’s pipeline assets; whether and when the FDA, EMA or any other applicable regulatory authorities may approve any such applications, which will depend on its assessment of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by the FDA, EMA or other regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of ARIAD’s products and ARIAD’s pipeline assets; and competitive developments; and those additional factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent quarterly and current reports on Form 10-Q and Form 8-K. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20170206005112r1&sid=acqr7&distro=nx&lang=en
View source version on businesswire.com: http://www.businesswire.com/news/home/20170206005112/en/
ARIAD Pharmaceuticals, Inc.
For Investors
Manmeet Soni, 617-503-7298
manmeet.soni@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
Source: ARIAD Pharmaceuticals, Inc.
© Copyright Business Wire 2017
Glad the company keeps us up to date with news often. Reading the announcements from Double Crown gives a very good picture of the progress they are making on all fronts. The Translock is certainly developing into an industry changing product that can make Double Crown a big winner for shareholders.
I agree this is the year all the pieces for DDCC are coming together. The Translock is ready to go into service with many different types of commodity transport, the patent protection is all set up, and marketing rights have been assigned exclusively to Double Crown Resources. With the rebound of the oil industry this year, Double Crown's oil drilling connections all over the world, and the new contract for use of the food preservation technology for agricultural shipments are setting up a great opportunity for this company.
I agree this is the year all the pieces for DDCC are coming together. The Translock is ready to go into service with many different types of commodity transport, the patent protection is all set up, and marketing rights have been assigned exclusively to Double Crown Resources. With the rebound of the oil industry this year, Double Crown's oil drilling connections all over the world, and the new contract for use of the food preservation technology for agricultural shipments are setting up a great opportunity for this company.
It was a very good week for DDCC. There was a lot of buying coming in daily and the stock closed at the high of the week on Friday. We are probably getting close to the first signed Translock contracts and more people are starting to realize how much this little company can be worth once those contracts begin. The world shipping markets are worth billions and growing every year. Translock can bring a lot of that money to Double Crown Resources and they are ready to begin.
I saw all that buying coming into DDCC on Monday also. The company is already setting up marketing deals for the Translock containers with several customers. The details were in the latest company news they issued at the start of January. That was a good update for investors. Seems more people are getting their shares before the news of the contract announcements come.
Loving the upward climb on ARIA that we are seeing. Certainly glad I got into this stock on the drop in November. It has almost doubled for me since then. I think the new year is looking very positive for investors.
Very good to see Double Crown start off the new year with updates on the Translock projects that are proceeding. Seeing projects in the oil and food service industries shows the wide application of Translock for many different types of products and it's already coming together in both fields. So 2017 should be the year for this company and all its investors as we see the Translock go into real use shipping real products for real customers. Also, very good to see that the patent protection is all set up and no one can copy the Translock.
Double Crown has numerous projects that they have laid out in 2016 and I am expecting to start seeing them coming together in a rewarding way next year too. The most important ones are centered around the Translock, of course, and I have to agree that getting the patents issued this year was probably the most important steps that were accomplished. I am looking forward to success with Double Crown from this point on.
Thanks, richbob, for your professional opinions on the Double Crown technology. I have read in your previous posts that you are in this industry so I always look to read your comments. On the food preservation tech that was just announced, it does seem logical that removing the oxygen would preserve the contents to a high degree. Perhaps this is the case and we should find out more in future news. The Translock container is getting more versatile and valuable all the time.
Strong news from Double Crown today. This Sealafresh company looks like they are ready to put the Translock to work and they have already done testing with a major agricultural shipper. This is real progress and the details about how much improvement this can bring to the way food products are shipped and how long they last in shipment show us how valuable this will be. Translock is such a high potential development. I am sure Double Crown will have great success, especially with partners like the one named today.
Happy Thanksgiving to all of the investors of Ariad Pharmaceuticals!
Happy Thanksgiving to all of the CVM investors!
Happy Thanksgiving, richbob, and all of the DDCC investors. Double Crown has given us plenty of good news to be thankful for in 2016 and I am sure there will be more to come with all that they are working on. Hope you have a great holiday!
Good take on DDCC being a two sided opportunity stock. There is both the Translock business, with applications to all of the world's shipping markets, should be worth many millions, and also in the same company, the mineral processing business. From the news the company has issued, both are moving ahead and it is really to this company's credit that they can have a dual business model and work on both at the same time.
BioTechs have been depressed going into the election because of the uncertainty factor, but once we see the winner, that uncertainty will be gone and I think it will be a good time for select BioTechs with the right elements to get back on the rise. I think Ariad Pharmaceuticals will be one of these.
Good find on the MarAd grant awards for improving and increasing marine shipping routes. This is right up Double Crown's alley with the Translock container system they have designed and should certainly favor contracts coming Double Crown's way for use of their state-of-the-art shipping technology. Thanks for posting.
Double Crown's Translock container will make every bulk product shipper that uses it more profitable over competitors who do not. That's the most compelling reason Translock will be the container of choice and it is only available from Double Crown. Just a matter of time before we see the first marketing contracts.
ARIAD Reaffirms Commitment to Discovering and Developing Treatments for Patients with Rare Cancers
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today acknowledged the receipt of a Congressional letter and reaffirmed its commitment to discovering and developing treatments for patients with rare cancers with the following statement:
ARIAD is a small, research-driven biotechnology company. Its mission is the discovery, development and delivery of highly innovative treatments for patients with rare cancers, including those with no other treatment options available today. The Company applies its deep in-house expertise and makes significant investments in research and development (R&D) to advance breakthrough treatments for patients.
The Company recognizes the high cost of innovative oncology drugs and believes in the importance and efficacy of its products. Importantly, to achieve its mission, ARIAD has invested more than $1.3 billion in R&D and accumulated losses of approximately $1.4 billion since the Company was founded, which have not been recovered. In 2015, ARIAD generated $119 million in total revenue and invested $171 million, or 143% of revenue, in R&D. After years of risk-taking and research, the Company has brought its first product to market serving a very small and seriously ill group of cancer patients. ARIAD remains fully committed to developing critical therapies for unserved and underserved small patient populations suffering from rare cancers.
The Company has received a letter from Rep. Cummings and Sen. Sanders requesting information and plans to respond to their request.
Forward-Looking Statements:
This press release contains forward-looking statements. Any statements contained herein which do not describe historical facts, including, but not limited to, statements regarding: our mission, our planned investments in R&D, and our commitment to our patients, are forward-looking statements which are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to, our ability to successfully commercialize and generate profits from sales of our products; our ability to meet anticipated clinical trial commencement, enrollment and completion dates and regulatory filing dates for our products and product candidates and to move new development candidates into the clinic; our ability to execute on our key corporate initiatives; regulatory developments and safety issues, including difficulties or delays in obtaining regulatory and pricing and reimbursement approvals to market our products; competition from alternative therapies; our reliance on the performance of third-party manufacturers and specialty pharmacies or our collaborators for the supply and distribution of our products and product candidates; the occurrence of adverse safety events with our products and product candidates; the costs associated with our research, development, manufacturing, commercialization and other activities; the conduct, timing and results of preclinical and clinical studies of our products and product candidates, including that preclinical data and early-stage clinical data may not be replicated in later-stage clinical studies; the adequacy of our capital resources and the availability of additional funding; the ability to satisfy our contractual obligations, including under our leases, convertible debt and royalty financing agreements; patent protection and third-party intellectual property claims; litigation; our operations in foreign countries; risks related to key employees, markets, economic conditions, health care reform, prices and reimbursement rates; and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.
About ARIAD:
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm)
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20161020006573r1&sid=acqr7&distro=nx&lang=en
View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006573/en/
ARIAD Pharmaceuticals, Inc.
For Investors:
Jennifer Robinson, 617-621-2286
Jennifer.Robinson@ariad.com
For Media:
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
Or
Joele Frank, Wilkinson Brimmer Katcher
Steve Frankel / Ed Trissel / Jed Repko, 212-355-4449
CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE MKT:CVM) announced today: following up on our press release issued on September 26, 2016, we have received the Partial Clinical Hold letter from the U.S. Food and Drug Administration (FDA). CEL-SCI has started working on a response to the FDA and will work diligently with the FDA to seek to have the partial clinical hold lifted.
About CEL-SCI Corporation
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the head and neck. Subject to the partial clinical hold, the study was designed with the objective that, if the study endpoint, which is an improvement in overall survival of the subjects treated with the Multikine treatment regimen plus the current standard of care (SOC) as compared to subjects treated with the current SOC only, is satisfied, the study results will be used to support applications that the Company plans to submit to regulatory agencies in order to seek commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase 1 trial of the former indication (treatment of cervical dysplasia in HIV/HPV co-infected women) has been completed at the University of Maryland. The latter indication (treatment of peri-anal warts in HIV/HPV co-infected men and women) is being studied in a Phase 1 trial at UCSF. CEL-SCI has issued patents on Multikine from the US, Europe, China, and Japan.
CEL-SCI also is developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis.
The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2015. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
*Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy have not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine. Further research is required, and early-phase clinical trial results must be confirmed in the Phase 3 clinical trial of this investigational therapy that is in progress and that is currently subject to a clinical hold on enrollment of additional new patients.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20161021005194r1&sid=acqr7&distro=nx&lang=en
View source version on businesswire.com: http://www.businesswire.com/news/home/20161021005194/en/
CEL-SCI Corporation
Gavin de Windt, 703-506-9460
Source: CEL-SCI Corporation
Double Crown gives investors a lot of information in their news. They also give news pretty often. The most important developments such as the patents and the marketing on the Translock and also the acquisition of the gold property in Mexico were explained in a lot of detail. Looking forward to more news, especially on revenue generation from these projects since they have now reached the point where they can start paying off.
Really glad Double Crown President Allen Lopez set the record straight in this letter to the DDCC shareholders on Oct. 12th. His official statements about the real plans of the company for the Translock and the new gold property in Mexico are all I needed to see. I suggest all shareholders make sure they read it so they will have their facts right.
http://globenewswire.com/news-release/2016/10/12/878938/0/en/Double-Crown-Resources-President-Reports-on-Progress-with-Intermodal-Transport-System.html
Really well presented letter to DDCC shareholders from President Allen Lopez. I was glad to read it this morning. I also just read the new feature and liked this part especially:
As for the opportunity Lopez is leading the company to, approximately $30 billion is spent every year delivering dry bulk goods. From a sheer tonnage perspective, about 4 billion tons of dry bulk goods were shipped by sea; much of that tonnage could have easily been shipped in Translock2 containers.
Double Crown's Translock containers are the best design ever created with cost saving features that every shipping company will want to use. With the Translock features under patent protection now, no other company will be able to copy them. Double Crown holds the winning cards and it's just a matter of time before we start to see what big shipping players will be paying up.
One thing I especially like about today's news is the mention that this Puebla region mine has a long history of significant gold and silver production ... Historically, the Puebla region mines have yielded an abundance of precious metals resources.
Double Crown acquires Puebla gold and silver mine in Mexico. That's a real deal event and another pretty big feather in the company's cap in addition to the Translock. They have talked about all the different mines that they have agreements with all throughout Latin America many times and now they have actually gained controlling interest in a big one that is ready to produce right away.
I can understand why this took a while to get done with all the different mines in different countries they had to research on and consider. Double Crown already has customers and contracts for the gold which they now own so it's definitely revenue time for this company. Great news.
Yes, hotstockz, Double Crown receiving the patent on the Translock system does effectively create a monopoly for the interlocking type container which can now only be marketed by Double Crown Resources. Competitors with designs that infringe on Double Crown's patented technology will have to pay Double Crown licensing fees or get out of the business. That's what the patent is all about and why it was so important that it was granted to Double Crown. The next thing we should see should be some very lucrative licensing contracts and I am very much looking forward to those announcements.
Exactly, all the shipping companies will want Double Crown's Translock because it is designed to cut their costs and that's what they care most about. Getting the patent rights for Translock on file was Double Crown's most important achievement so far. And now they have also told us they are in licensing talks with the big container makers and users at this time. It's all coming together for Double Crown and investors who see the whole picture.
No question that the Translock is the best new technology to enter the container shipping market since the first containers were invented. The U.S. Patent Office awarded the patent to Translock over all competing designs because of the advanced features which are now only available from Double Crown. There is no other company that can offer this advancement in interlocking container design. Just a matter of time before we start seeing the first licensing deals with all the big shipping companies and container manufacturers.
Very informative article covering the growth in commodity shipping markets at exactly the places where Double Crown's Translock containers will be most useful. The author, Matthew Briar did some excellent research work on this piece. Translock has a perfect opportunity now.
All the work that has gone into designing and building the Translock is going to pay off for everyone invested in DDCC. The advantages of the Translock are explained very clearly in Double Crown's presentation: http://www.doublecrownresources.com/index.php/news-media/media
Yes, chiefs, I remember that event and Double Crown did invite everyone to attend. I wish I could have gone myself but I am glad many people did make it there and all reported that it was a very impressive presentation. As I remember, they said many high level industry people were there, too, not just Double Crown shareholders. I think this was mainly because of the Translock.
The coverage of the major event of Double Crown's patent issue for the Translock is very good to see and very well researched. This new article from Peter Graham covers the reasons that Translock will change the shipping industry from this point on. The Translock is a new state of the art and anyone who does the reading can clearly see why.
MetalsNews.com taking note of the Double Crown announcement yesterday is very significant. This is a mainline mining industry online journal that is read by many professionals in the mining industry. Seeing their editors give Double Crown specific coverage is very gratifying. With this reference, readers will be able to go see the Translock on Double Crown's own site, including photos of the completed Translock units that have been built.
Great news and its getting Double Crown lots of new attention today. Thanks for the chart showing the nice uptic in the price, but there is so much more to be gained from these low levels. I think this is a great entry point for anyone finding DDCC now. With the Translock patent in place and marketing deals on the way, I can see this stock at 100 times its current value or more considering the size of the worldwide container market and the billions of dollars it represents.
Good info there, hotstockz. The Translock has very great potential and offers just what the markets need. I see a lot of volume in DDCC today. New investors are taking note and getting in here. I am excited for the future of Double Crown.